You are here

Molecular Medicine awards Ross Prize to Dr. Huda Zoghbi

HOUSTON, TX – (March 08, 2018) – Dr. Huda Zoghbi, director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Howard Hughes Medical Institute investigator and professor at Baylor College of Medicine, has been awarded the sixth annual Ross Prize in Molecular Medicine by The Feinstein Institute for Medical Research at Northwell Health.

The Ross Prize is awarded annually by Molecular Medicine to scientists who have made a demonstrable impact in the understanding of human diseases pathogenesis and/or treatment, and who hold significant promise for making even greater contributions to the general field of molecular medicine.

“It is an honor to be recognized by Molecular Medicine and to join the prestigious roster of past Ross Prize recipients,” said Zoghbi, professor in the Departments of Pediatrics, Molecular and Human Genetics, Neurology and Neuroscience at Baylor. “I look forward to discussing my work and furthering a dialog that I hope will encourage young trainees to join the fields of neurobiology and molecular medicine.”

The prize, which includes a $50,000 award, will be presented to Zoghbi on June 5 at the New York Academy of Sciences in New York City, followed by lectures from Zoghbi and other eminent researchers. The Ross Prize is awarded through the Feinstein Institute’s peer-reviewed, open-access journal, Molecular Medicine, and made possible by the generosity of Feinstein Institute board members Robin and Jack Ross.

“Huda Zoghbi’s examination of the genetic causes for neurological diseases, such as spinocerebellar ataxia and Rett syndrome, has led to a better understanding of neurobiology,” said Feinstein Institute President and Chief Executive Officer Dr. Kevin J. Tracey, who also serves as editor emeritus of Molecular Medicine. “It is through her discoveries that researchers are able to identify new, potential therapies for these conditions that currently have no cure.”

Zoghbi’s research focuses on identifying the genetic causes of neurodegenerative and neurodevelopmental diseases and a broader understanding of neurobiology. Her lab, along with Harry Orr’s team at the University of Minnesota, discovered that excessive repeats of the DNA segment, CAG, in the ATAXIN-1 gene causes the neurodegenerative disease spinocerebellar ataxia type 1 (SCA1). SCA1 is a progressive movement disorder that begins in childhood and progressively causes problems with coordination and balance (ataxia), speech and swallowing difficulties, muscle stiffness, and weakness in the muscles that control eye movement. Over time, SCA1 may cause mental impairment, numbness, tingling or pain in the arms and legs and uncontrolled muscle tensing, wasting and twitches. Understanding the genetic cause for SCA1 has inspired additional research that may identify a therapeutic strategy for this condition.

Zoghbi’s lab also has identified the genetic mutations that cause Rett syndrome. Rett syndrome mostly targets young girls and is a postnatal neurological disorder which causes problems in diverse brain functions ranging from cognitive, sensory, emotional, and motor to autonomic functions. These can affect learning, speech, sensations, mood, movement, breathing, cardiac function and even chewing, swallowing and digestion. Dr. Zoghbi’s discoveries provide a framework for understanding this disorder as well as the MECP2 duplication disorder and for charting a path for potential therapeutic interventions.

Past recipients of the Ross Prize are Jeffrey V. Ravetch, M.D., Ph.D., the Theresa and Eugene M. Lang professor and head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at the Rockefeller University; Charles N. Serhan, Ph.D., director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital, the Simon Gelman Professor of Anaesthesia at Harvard Medical School and professor at Harvard School of Dental Medicine; Lewis C. Cantley, Ph.D., the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital; John J. O’Shea, M.D., scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases; and Dan R. Littman, M.D., Ph.D., the Helen L. and Martin S. Kimmel Professor of Molecular Immunology in the Skirball Institute of Biomolecular Medicine at New York University School of Medicine.

To learn more about the Ross Prize celebration and symposium, and to register for the event, please visit www.nyas.org/RossPrize2018.

Thursday, March 8, 2018